Oncology Consortium

Impactful Education Through Innovative Engagement

roy.berger@theoncologyconsortium.com | (516) 729-0303

Henry S. Friedman, MD

Neuro-Oncology Consortium

Dr. Henry S. Friedman is an internationally renowned academic adult and pediatric neuro-oncologist who helps to lead The Preston Robert Tisch Brain Tumor Center at Duke University. He is the author of more than 500 peer reviewed articles, reviews, and book chapters and has presented extensively at both international and national meetings.

Adam Mamelak, MD

Neuro-Oncology Consortium

Dr. Adam Mamelak is Professor of Neurosurgery and Co-director of the Pituitary Center at Cedars-Sinai Medical Center in Los Angeles. His primary interests encompass pituitary and skull base surgery, epilepsy and brain tumors.

Michael D. Prados, MD

Neuro-Oncology Consortium

Michael Prados was a Fellow in Neuro-Oncology at the University of California San Francisco in 1985. Following a two year training program, he was recruited to the Faculty in 1988 and has remained at UCSF since that time, and is now Professor-in-Residence and the Charles B Wilson Chair of Neurosurgery. His career interests center around patient care, and clinical and translational research. He became the Project Leader of the North America Brain Tumor Consortium (NABTC) and led that group for 15 years. When the NABTC merged with the NABTT (and became the Adult Brain Tumor Consortium) he was named co-Project Leader. In 2009, he was awarded the Project Leadership of the Ivy Foundation Early Phase Clinical Trials Consortium, a group of now 7 major academic centers who conduct clinical and translation research in adults with brain cancer.

John H. Sampson, MD, PhD, MBA, MHSc

Neuro-Oncology Consortium

Dr. Sampson is a Chief of Neurosurgery at Duke University with doctoral level training in Immunology and an MBA from a top Business School whose research interest is in brain tumor drug delivery and immunotherapy -- activating a patient’s immune system to recognize and kill tumors. His research examines the ability of immune cells to specifically target tumor cells with little to no normal cell toxicity. He has already developed two vaccines targeting tumor-specific antigens that promises to extend the lifespan of patients with brain tumors in prospective, randomized, and placebo-controlled trials. He is currently the PI of several international trials for immunotherapy in brain tumors based on his own work and work from global pharmaceutical companies.

Download Capability Slide

Oncology Consortium | All Rights Reserved 2012-2017
Back to Top